Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis

Clinical Neuropharmacology

Volumn 33, Issue 1, 2010, Pages 17-21

  Parry, Gareth J ^a   Rodrigues, Cecilia M P ^b   Aranha, Marcia M ^b   Hilbert, Sarah J ^a   Davey, Cynthia ^c   Kelkar, Praful ^a   Low, Walter C ^a   Steer, Clifford J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b IMedUL ^*  (Portugal)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLADDER INFECTION; BLOATING; BLOOD BRAIN BARRIER; CATARACT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FALLING; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HUMAN; INFECTION; INSOMNIA; MALE; MEMORY DISORDER; MUSCLE CRAMP; MUSCLE TWITCH; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; UNSTEADINESS; UPPER RESPIRATORY TRACT INFECTION; URINE COLOR; VERTIGO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; BILE ACIDS AND SALTS; BLOOD-BRAIN BARRIER; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 76749123407     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181c47569     Document Type: Article

References (24)

1. Rowland L, Shneider N. Am-otrophic lateral sclerosis N Engl J Med 2001;344:1688-1700.
2. Almer G, Guegan C, Teismann P, et al. Increased expression of the pro-inflammator- enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis Ann Neurol 2001;49:176-185.
3. Li M, Ona VO, Chen M, et al. Functional role and therapeutic implications of neuronal caspase-1 and-3 in a mouse model of traumatic spinal cord injur- Neuroscience 2000;99:333-342.
4. Martin LJ. Neuronal death in am-otrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism J Neuropathol Exp Neurol 1999;58:459-471.
5. Schiffer D, Cordera S, Cavalla P, et al. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139(suppl):27- 33.
6. Beuers U. Drug insight: mechanisms and sites of action of ursodeox-cholic acid in cholestasis Nat Clin Pract Gastroenterol Hepatol 2006;3:318-328.
7. Invernizzi P, Setchell KD, Crosignani A, et al. Differences in the metabolism and disposition of ursodeox-cholic acid and its taurine-conjugated species in patients with primary biliary cirrhosis Hepatology 1999;29:320-327.
8. Keene CD, Rodrigues CM, Eich T, et al. Tauroursodeox-cholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease Proc Natl Acad Sci U S A 2002;99:10671-10676.
9. Rodrigues CM, Sola S, Nan Z, et al. Tauroursodeox-cholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats Proc Natl Acad Sci U S A 2003;100:6087-6092.
10. Rodrigues CM, Spellman SR, Sola S, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab 2002;22:463-471.
11. Duan WM, Rodrigues CM, Zhao LR, et al. Tauroursodeox-cholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant 2002;11:195-205.
12. Ved R, Saha S, Westlund B, et al. Similar patterns of mitochondrial vulnerabilit- and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 2005;280:42655-42668.
13. Boatright JH, Moring AG, McElro- C, et al. Tool from ancient pharmacopoeia prevents vision loss. Mol Vis 2006;12:1706-1714.
14. Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transth-retin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008;1782:517-522.
15. Colak A, Kelten B, Sagmanligil A, et al. Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. J Clin Neurosci 2008;15:665-671.
16. Brooks BR, Miller RG, Swash M, et al. Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
17. Setchell KD, Worthington J. A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phase octadecylsilane bonded silica cartridges. Clin Chim Acta 1982;125:135-144.
18. Ward A, Brogden RN, Heel RC, et al. Ursodeox-cholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 1984;27:95-131. (Pubitemid 14223113)
19. Crosignani A, Setchell KD, Invernizzi P, et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996;30:333-358.
20. Sola S, Castro RE, Laires PA, et al. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med 2003;9:226-234.
21. Dewil M, Lambrechts D, Sciot R, et al. Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2007;33:499-509.
22. Eve DJ, Dennis JS, Citron BA. Transcription factor p53 in degenerating spinal cords. Brain Res 2007;1150:174-181.
23. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-1053.
24. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-784.